Module 2: Pathology and Biomarkers
Module 2: Pathology and Biomarkers is organized by Physicians' Education Resource, LLC (PER).
Release Date: January 31, 2023
Expiration Date: January 31, 2024.
Description:
An increasing number of oncologists are focusing their clinical practices on the treatment of breast cancer, creating a need for specialized education. The School of Breast Oncology®, which has been held annually since 2003, was developed to advance patient care by providing a curriculum-based program focused exclusively on breast cancer clinical management. The intensive 3-day interactive program provides a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention, and treatment, with lectures emphasizing clinical implications presented by leading clinical investigators.
This educational activity is an archive of the live program held from November 3 to 5, 2022.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Review breast cancer biology, molecular subtyping, staging, and prognostic and/or predictive biomarkers to better individualize therapy and counsel patients regarding conventional and investigational treatment options
• Integrate genomic and molecular biomarkers and gene expression assays into treatment planning to optimize patient outcomes
• Discuss the application of current and evolving imaging options for diagnosing, staging, and monitoring breast cancer
• Incorporate current guidelines and evolving evidence about local treatment options, including advances in surgery and radiation therapy
• Take into consideration efficacy and safety data, expert guidelines, patient characteristics and comorbidities, and genomic and/or molecular tumor information to individualize selection of systemic therapies for patients with early-stage or advanced/metastatic disease
• Evaluate emerging clinical data and/or evolving treatment strategies and apply clinical trial data to optimize individual outcomes
• Prevent or manage treatment-related adverse events with supportive care strategies
• Facilitate awareness of clinical trial opportunities based on knowledge of emerging approaches and variances in care.
Additional Details Will Be Posted as Soon as Information is Available.